Syndax Pharmaceuticals (SNDX) Stock Analysis & Winston Score

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company that develops drugs to treat blood cancers and other serious diseases. Its two lead medicines are revumenib, which targets a specific genetic mutation in acute leukemia, and axatilimab, which treats a condition called chronic graft-versus-host disease — a complication that can occur after bone marrow transplants. Revumenib received FDA approval in late 2024 under the brand name Revuforte, marking a major milestone for the company. Syndax makes money by selling its approved drug and through partnership agreements with larger pharmaceutical companies. It operates primarily in the United States, though it has licensing deals that extend its reach internationally. The company is still spending far more than it earns, which is typical for early-stage biotechs — its operating margin is deeply negative. The key growth driver is the commercial ramp of revumenib, but the main risk is whether sales can grow fast enough to offset ongoing research and development costs before the company needs to raise more cash.